Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, Simonelli M, Perrino M, Bruzzone A, Thunnissen E, Tunesi G, Giordano L, Roncalli M, Peters GJ, Santoro A. Zucali PA, et al. Among authors: bruzzone a. Clin Cancer Res. 2011 Apr 15;17(8):2581-90. doi: 10.1158/1078-0432.CCR-10-2873. Epub 2011 Jan 24. Clin Cancer Res. 2011. PMID: 21262916 Clinical Trial.
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, Soto-Parra H, De Vincenzo F, Bruzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L, Santoro A. Ceresoli GL, et al. Among authors: bruzzone a. Br J Cancer. 2013 Aug 6;109(3):552-8. doi: 10.1038/bjc.2013.368. Epub 2013 Jul 16. Br J Cancer. 2013. PMID: 23860535 Free PMC article. Clinical Trial.
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.
Ceresoli GL, Grosso F, Zucali PA, Mencoboni M, Pasello G, Ripa C, Degiovanni D, Simonelli M, Bruzzone A, Dipietrantonj C, Piccolini E, Beretta GD, Favaretto AG, Giordano L, Santoro A, Botta M. Ceresoli GL, et al. Among authors: bruzzone a. Br J Cancer. 2014 Jul 15;111(2):220-6. doi: 10.1038/bjc.2014.312. Epub 2014 Jun 10. Br J Cancer. 2014. PMID: 24918816 Free PMC article.
Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos.
Filiberti R, Marroni P, Spigno F, Merlo DF, Mortara V, Caruso P, Cioè A, Michelazzi L, Bruzzone A, Bobbio B, Simonassi C, Del Corso L, Galli R, Racchi O, Dini G, Linares R, Mencoboni M. Filiberti R, et al. Among authors: bruzzone a. Oncology. 2014;86(1):33-43. doi: 10.1159/000355687. Epub 2013 Dec 21. Oncology. 2014. PMID: 24401539
Individual predictors of increased serum mesothelin in asbestos-exposed workers.
Filiberti R, Marroni P, Mencoboni M, Mortara V, Caruso P, Cioè A, Michelazzi L, Merlo DF, Bruzzone A, Bobbio B, Del Corso L, Galli R, Taveggia P, Dini G, Spigno F. Filiberti R, et al. Among authors: bruzzone a. Med Oncol. 2013 Mar;30(1):422. doi: 10.1007/s12032-012-0422-6. Epub 2013 Jan 1. Med Oncol. 2013. PMID: 23277285
Induction chemotherapy in head and neck cancer patients followed by concomitant docetaxel-based radiochemotherapy.
Mencoboni M, Grillo-Ruggieri F, Salami A, Scasso F, Rebella L, Grimaldi A, Dellepiane M, Moratti G, Bruzzone A, Spigno F, Ghio R, Figliomeni M. Mencoboni M, et al. Among authors: bruzzone a. Eur J Cancer Care (Engl). 2011 Jul;20(4):503-7. doi: 10.1111/j.1365-2354.2010.01185.x. Epub 2010 Apr 30. Eur J Cancer Care (Engl). 2011. PMID: 20477856 Clinical Trial.
Solitary fibrous tumor.
Bruzzone A, Varaldo M, Ferrarazzo C, Tunesi G, Mencoboni M. Bruzzone A, et al. Rare Tumors. 2010 Dec 31;2(4):e64. doi: 10.4081/rt.2010.e64. Rare Tumors. 2010. PMID: 21234256 Free PMC article.
Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis.
Aquino S, Clavio M, Rossi E, Vignolo L, Miglino M, Spriano M, Canepa L, Catania G, Pierri I, Bergamaschi M, Gonella R, Marani C, Racchi O, Cavaliere M, Goretti R, Carbone F, Bruzzone A, Tassara R, Carella AM, Ghio R, Gobbi M. Aquino S, et al. Among authors: bruzzone a. Oncol Lett. 2011 Mar;2(2):289-295. doi: 10.3892/ol.2011.255. Epub 2011 Jan 21. Oncol Lett. 2011. PMID: 22866079 Free PMC article.
Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
Balleari E, Clavio M, Arboscello E, Bellodi A, Bruzzone A, Del Corso L, Lucchetti MV, Miglino M, Passalia C, Pierri I, Ponassi I, Oneto C, Racchi O, Scudeletti M, Vignolo L, Zoppoli G, Gobbi M, Ghio R. Balleari E, et al. Among authors: bruzzone a. Leuk Res. 2011 Nov;35(11):1472-6. doi: 10.1016/j.leukres.2011.05.025. Epub 2011 Jul 26. Leuk Res. 2011. PMID: 21794914
49 results